{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:37:09Z","timestamp":1790869029706,"version":"4.1.0"},"reference-count":33,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2011,9,13]],"date-time":"2011-09-13T00:00:00Z","timestamp":1315872000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0024844","type":"journal-article","created":{"date-parts":[[2011,9,13]],"date-time":"2011-09-13T21:30:10Z","timestamp":1315949410000},"page":"e24844","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":15,"title":["Styryl-Based and Tricyclic Compounds as Potential Anti-Prion Agents"],"prefix":"10.1371","volume":"6","author":[{"given":"Erika","family":"Chung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances","family":"Prelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Dealler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woo Sirl","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Tae","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Wisniewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2011,9,13]]},"reference":[{"key":"ref1","article-title":"Prions and protein folding diseases.","author":"E Norrby","year":"2011","journal-title":"J Intern Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1586\/erv.10.131","article-title":"Immunomodulation for Prion and Prion Related Diseases.","volume":"9","author":"T Wisniewski","year":"2010","journal-title":"Expert Rev Vaccines"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1146\/annurev.pathmechdis.3.121806.154326","article-title":"Molecular Mechanisms of Prion Pathogenesis.","volume":"3","author":"A Aguzzi","year":"2008","journal-title":"Annu Rev Pathol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1021\/bi900108v","article-title":"Prion diseases and their biochemical mechanisms.","volume":"48","author":"NJ Cobb","year":"2009","journal-title":"Biochem"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/ana.21420","article-title":"A novel human disease with abnormal prion protein sensitive to protease.","volume":"63","author":"P Gambetti","year":"2008","journal-title":"Ann Neurol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1093\/brain\/awl150","article-title":"A systematic review of prion therapeutics in experimental models.","volume":"129","author":"CR Trevitt","year":"2006","journal-title":"Brain"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1212\/01.wnl.0000302186.10596.f6","article-title":"Transmissible spongiform encephalopathy in the 21st century: neuroscience for the clinical neurologist.","volume":"70","author":"P Brown","year":"2008","journal-title":"Neurol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1586\/14787210.7.1.83","article-title":"Therapeutic interventions ameliorating prion disease.","volume":"7","author":"MW Brazier","year":"2009","journal-title":"Expert Rev Anti Infect Ther"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2217\/imt.10.3","article-title":"Immunotherapy for prion diseases: opportunities and obstacles.","volume":"2","author":"L Li","year":"2010","journal-title":"Immunotherapy"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"13794","DOI":"10.1128\/JVI.79.21.13794-13796.2005","article-title":"Interspecies transmission of chronic wasting disease prions to squirrel monkeys (Saimiri sciureus).","volume":"79","author":"RF Marsh","year":"2005","journal-title":"J Virol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1051\/vetres:2008018","article-title":"A prion disease of cervids: chronic wasting disease.","volume":"39","author":"CJ Sigurdson","year":"2008","journal-title":"Vet Res"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.3201\/eid1509.090253","article-title":"Susceptibilities of nonhuman primates to chronic wasting disease.","volume":"15","author":"B Race","year":"2009","journal-title":"Emerg Infect Dis"},{"key":"ref13","first-page":"406","article-title":"Evaluation of anti-prion activity of congo red and its derivatives in experimentally infected hamsters.","volume":"54","author":"G Poli","year":"2004","journal-title":"Arzneimittelforschung"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/j.1471-4159.2006.04035.x","article-title":"Styrylbenzoazole derivatives for imaging of prion plaques and treatment of transmissible spongiform encephalopathies.","volume":"99","author":"K Ishikawa","year":"2006","journal-title":"J Neurochem"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"10729","DOI":"10.1128\/JVI.01075-07","article-title":"Mechanistic insights into prion curing by novel anti-prion compounds.","volume":"81","author":"S Webb","year":"2007","journal-title":"J Virol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"12889","DOI":"10.1128\/JVI.01563-07","article-title":"Orally administered amyloidophilic compound is effective in prolonging the incubation periods of animals cerebrally infected with prion diseases in a prion strain-dependent manner.","volume":"81","author":"Y Kawasaki","year":"2007","journal-title":"J Virol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"9836","DOI":"10.1073\/pnas.161274798","article-title":"Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease.","volume":"98","author":"C Korth","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2174\/187152709789541961","article-title":"Psychotropic medications and the treatment of human prion diseases.","volume":"8","author":"BS Appleby","year":"2009","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1002\/cbic.200700154","article-title":"Stryl-based compounds as potential in vivo imaging agents for \u03b2-amyloid plaques.","volume":"8","author":"Q Li","year":"2007","journal-title":"Chembiochem"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.nbd.2009.01.013","article-title":"Anti-PrP Mab 6D11 suppresses PrP<sup>Sc<\/sup> replication in prion infected myeloid precursor line FDC-P1\/22L and in the lymphoreticular system <italic>in vivo<\/italic>.","volume":"34","author":"MJ Sadowski","year":"2009","journal-title":"Neurobiol Dis"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1111\/j.1460-9568.2006.04805.x","article-title":"Clearance and prevention of prion infection in cell culture by anti-PrP antibodies.","volume":"24","author":"J Pankiewicz","year":"2006","journal-title":"Eur J Neurosci"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJM200105173442006","article-title":"Neurodegenerative diseases and prions.","volume":"344","author":"SB Prusiner","year":"2001","journal-title":"N Eng J Med"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"10288","DOI":"10.1128\/JVI.77.19.10288-10294.2003","article-title":"New inhibitors of scrapie-associated prion protein formation in a library of 2000 drugs and natural products.","volume":"77","author":"DA Kocisko","year":"2003","journal-title":"J Virol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"8462","DOI":"10.1128\/JVI.77.15.8462-8469.2003","article-title":"Evaluation of quinacrine treatment for prion diseases.","volume":"77","author":"A Barret","year":"2003","journal-title":"J Virol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/ana.10336","article-title":"Quinacrine does not prolong survival in a murine Creutzfeldt-Jakob disease model.","volume":"52","author":"SJ Collins","year":"2002","journal-title":"Ann Neurol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1126\/science.299.5604.191","article-title":"New perspectives for prion therapeutics meeting. Prion disease treatment&apos;s early promise unravels.","volume":"299","author":"P Follette","year":"2003","journal-title":"Science"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1128\/JVI.69.1.506-508.1995","article-title":"Congo red prolongs the incubation period in scrapie-infected hamsters.","volume":"69","author":"L Ingrosso","year":"1995","journal-title":"J Virol"},{"key":"ref28","first-page":"36","article-title":"CpG oligodeoxynucleotide-enhanced humoral immune response and production of antibodies to prion protein PrPSc in mice immunized with 139A scrapie-associated fibrils.","volume":"14","author":"DS Spinner","year":"2007","journal-title":"J Leukoc Biol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.neuroscience.2008.02.051","article-title":"High titers of mucosal and systemic anti-PrP antibodies abrogates oral prion infection in mucosal vaccinated mice.","volume":"153","author":"F Goni","year":"2008","journal-title":"Neurosci"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0006-8993(98)00833-6","article-title":"Astrocytosis and amyloid deposition in scrapie-infected hamsters.","volume":"809","author":"X Ye","year":"1998","journal-title":"Brain Res"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/1471-2202-11-130","article-title":"Anti-PrP<sup>C<\/sup> monoclonal antibody infusion as a novel treatment for A\u03b2 oligomer cognitive cognitive deficits.","volume":"11","author":"E Chung","year":"2010","journal-title":"BMC Neuroscience"},{"key":"ref32","first-page":"18787","article-title":"Blocking the apolipoproteinE\/Amyloid \u03b2 interaction reduces the parenchymal and vascular amyloid-\u03b2 deposition and prevents memory deficit in AD transgenic mice.","volume":"103","author":"M Sadowski","year":"2006","journal-title":"Proc Natl Acad Sci (USA)"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0002-9440(10)63355-X","article-title":"Blocking the apolipoprotein E\/\u00df-amyloid interaction reduces \u03b2-amyloid toxicity and decreases \u03b2-amyloid load in transgenic mice.","volume":"165","author":"M Sadowski","year":"2004","journal-title":"Am J Pathol"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0024844","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T19:48:59Z","timestamp":1592941739000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0024844"}},"subtitle":[],"editor":[{"given":"Sophie","family":"Mouillet-Richard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2011,9,13]]},"references-count":33,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2011,9,13]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0024844","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,13]]}}}